Pharmaceutical News

RSS

FAU study explores how a new drug may help treat PTSD and its common companions

About 12 million adults in the United States are affected by PTSD, impacting between 4% and 8% of the adult population – and up to 30% of military personnel and veterans.

24 Sep 2025

Trump claims ‘no downside’ to avoiding Tylenol during pregnancy. He’s wrong.

Obstetricians have long advised their pregnant patients that Tylenol is the safest option to reduce fever or pain. President Donald Trump stood before a national audience on Sept. 22 and contradicted that.

24 Sep 2025

Improving medication access in primary care with pharmacy technician support

This study examined whether adding pharmacy technicians to primary care teams relieved clinicians and nurses of medication-access tasks and improved perceptions of burden, quality of care and patient access.

23 Sep 2025

‘Sick to my stomach’: Trump distorts facts on autism, tylenol, and vaccines, scientists say

Ann Bauer, a researcher who studies Tylenol and autism, felt queasy with anxiety in the weeks leading up to the White House's much-anticipated autism announcement.

22 Sep 2025

New quintuple agonist shows promise for treating obesity and type 2 diabetes

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists (dual agonists such tirzepatide).

21 Sep 2025

Why universal COVID-19 vaccine guidance offers stronger protection than high-risk-only policies

The US Scenario Modeling Hub’s nine-team ensemble projected COVID-19 hospitalizations and deaths for April 2024 to April 2025 under six policy and immune-escape scenarios. Burden was similar to the prior year, with universal vaccination recommendations averting more outcomes than high-risk-only guidance, especially for adults aged 65 years and older.

21 Sep 2025

Survey reveals why some people turn to unregulated cannabis to treat medical conditions

Use of medical cannabis has been on the rise since it first became available to Utah patients in 2020. A medical cannabis card, which can be prescribed for difficult-to-treat conditions including PTSD and chronic pain, allows a patient to access licensed cannabis products in designated pharmacies.

19 Sep 2025

New findings support low-dose ATG to delay progression of type 1 diabetes

New research presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published simultaneously in The Lancet shows that a much lower dose than previously thought of the old immunomodulatory drug anti-thymocyte globulin (ATG) is safe and effective in preventing progression of type 1 diabetes (T1D) in young people.

19 Sep 2025

Study reveals early nicotinamide use reduces risk of aggressive skin cancers

A large U.S. Department of Veterans Affairs cohort study found that Nicotinamide use was associated with a 14% lower risk of new keratinocyte skin cancers, driven by a 22% reduction in cSCC and no reduction in BCC. The strongest benefit (56% lower risk) appeared when nicotinamide was started after a patient’s first skin cancer, with diminishing returns after multiple cancers.

18 Sep 2025

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with obesity but no diabetes. It also improved multiple cardiometabolic markers with a safety profile similar to other GLP-1 receptor agonists.

18 Sep 2025

Mobile app improves reporting of suspected adverse drug reactions in Uganda

Results from a ground-breaking new trial published in The Lancet Global Health show that a mobile application, Med Safety, improved the reporting of suspected adverse drug reactions (ADRs) by healthcare workers in Uganda.

18 Sep 2025

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major cardiovascular events compared to those taking other diabetes or weight-loss medications, new research has shown.

17 Sep 2025

University of Maine team develops sustainable method to cut drug production costs

One of the main factors driving prices in pharmaceuticals, such as cholesterol-lowering drugs and antibiotics, is the cost of production and materials.

17 Sep 2025

Prenatal exposure to opioid analgesics not linked to increased risk of autism or ADHD

Previous studies have suggested that children exposed to opioid pain medications while in the womb have higher rates of autism spectrum disorder (ASD) and attention- deficit/hyperactivity disorder (ADHD), but a new study finds that any increased risk could be explained by other factors.

16 Sep 2025

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated with GLP-1 receptor agonist medicines alone.

16 Sep 2025

Individuals taking semaglutide for weight loss experience less food noise than before

New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that individuals who are taking semaglutide for weight loss experience less food noise than before.

16 Sep 2025

Foods taste sweeter or saltier than before for some people taking Ozempic, Wegovy or Mounjaro

New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that some individuals who are taking Ozempic, Wegovy or Mounjaro find that foods taste sweeter or saltier than before.

16 Sep 2025

GLP-1 drugs may offer cost-effective treatment for people with knee osteoarthritis and obesity

A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee osteoarthritis and obesity, with tirzepatide providing greater health benefits at lower cost compared to semaglutide.

16 Sep 2025

Limited uptake of over-the-counter naloxone despite initial surge in sales

Sales of the overdose reversal medication naloxone increased after it was made available to the public without a prescription but then dipped quickly in the period following debut of over-the-counter sales, according to a new RAND study.

16 Sep 2025

Study: Half of adults without diabetes taking weight-loss drug discontinue treatment within a year

The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight.

15 Sep 2025

1
2
3
4
...
1454
Next

Pharmaceutical News

FAU study explores how a new drug may help treat PTSD and its common companions

Trump claims ‘no downside’ to avoiding Tylenol during pregnancy. He’s wrong.

Improving medication access in primary care with pharmacy technician support

‘Sick to my stomach’: Trump distorts facts on autism, tylenol, and vaccines, scientists say

New quintuple agonist shows promise for treating obesity and type 2 diabetes

Why universal COVID-19 vaccine guidance offers stronger protection than high-risk-only policies

Survey reveals why some people turn to unregulated cannabis to treat medical conditions

New findings support low-dose ATG to delay progression of type 1 diabetes

Study reveals early nicotinamide use reduces risk of aggressive skin cancers

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

Mobile app improves reporting of suspected adverse drug reactions in Uganda

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

University of Maine team develops sustainable method to cut drug production costs

Prenatal exposure to opioid analgesics not linked to increased risk of autism or ADHD

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

Individuals taking semaglutide for weight loss experience less food noise than before

Foods taste sweeter or saltier than before for some people taking Ozempic, Wegovy or Mounjaro

GLP-1 drugs may offer cost-effective treatment for people with knee osteoarthritis and obesity

Limited uptake of over-the-counter naloxone despite initial surge in sales

Study: Half of adults without diabetes taking weight-loss drug discontinue treatment within a year

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News